News

AddToAny

Google+ Facebook Twitter Twitter

Liquid biopsy and mathematical modelling

An evolutionary model utilising serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalised waiting time for progression.

The claim comes in a paper in Cancer Discovery – a journal of the American Association for Cancer Research.

Study author Andrea Sottoriva said: “By combining frequent longitudinal sampling of cell-free DNA with mathematical modelling of tumour evolution, we were able to make statistical predictions of patients who were at risk of progression.

“We could also determine when a cancer was going to come back, on a patient-by-patient basis. This is the first time that quantitative forecasting of this sort has been successfully used in cancer.”

The model utilising CEA measurements was applied to six patients to predict time to clinical progression. Of these predictions, three were within 10% of progression time as measured by RECIST.

Predictions generated with high sensitivity cfDNA profiling allowed for the prediction of progression time several weeks in advance, compared with models utilising CEA.

Information garnered from the cfDNA, can be used to generate multiple models based on the predicted growth of individual subclones driven by different mutations.

Image credit | Science Photo Library 

Related Articles

Clinical chemistry classics: tumour markers

This series on tumour markers concludes with a review of pioneering work in the development, analysis and clinical application of an important serum tumour marker – prostate specific antigen.

Non-invasive blood glucose test

A promising evaluation has been published on new technology to monitor blood glucose levels without needles or a finger prick.

Journals iStock

Journal-based learning exercises - November 2018

Each article’s contents should be read, researched and understood, and you should then come to a decision on each question. The pass mark is 17 out of 20 questions answered correctly. JBL exercises may be completed at any time until the published deadline date. Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

Download PDF

Clinical chemistry classics: tumour markers

The series on tumour markers continues with a brief review of pioneering work in the development, analysis and clinical application of an important serum tumour marker- CA19-9.

Top